A novel cell-free single-molecule unique primer extension resequencing (cf-SUPER) technology for bladder cancer non-invasive detection in urine
2020 Translational Andrology and Urology. All rights reserved..
BACKGROUND: The clinical diagnostic method for bladder cancer is cystoscopy, an invasive, expensive and inconvenient clinical test. Using urinary cell-free DNA (cfDNA) to develop non-invasive test for bladder cancer was a promising liquid biopsy.
METHODS: To improve the using rate of cfDNA template and decrease the PCR bias for liquid biopsy using urinary cfDNA, we developed a cell-free single-molecule unique primer extension resequencing (cf-SUPER) technology which was done for 29 matched urinary cfDNA and tumor DNA samples of bladder cancer patients to evaluate consistency of mutation profiles. Then, a 22 high mutational frequence genes was selected to form an uriprier panel, which was analyzed in 100 patients (47 bladder cancer cases and 53 controls) using cf-SUPER technology. This performance of the technology was evaluated using bioinformatic tools and clinical samples.
RESULTS: The study showed that cf-SUPER technology can accurately detect mutations with allele fractions even low as 0.01% and the DNA input as low as 1 ng. The consistency of mutation profiles and clinical pathological diagnose between 29 matched urinary cfDNA and tumor DNA samples was respectively 82.76% and 89.66% by using cf-SUPER technology. Using cf-SUPER technology, the sensitivity and specificity were 98%, 94% respectively for uriprier panel in non-invasive test.
CONCLUSIONS: The preliminary work shows that cf-SUPER technology will be a promising method for liquid biopsy. Focusing urinary cfDNA, the non-invasive diagnose and monitoring of bladder cancer can come true by using cf-SUPER technology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Translational andrology and urology - 9(2020), 3 vom: 03. Juni, Seite 1222-1231 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhao, Cheng [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bladder cancer |
|---|
| Anmerkungen: |
Date Revised 15.04.2022 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.21037/tau-19-774 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31252773X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31252773X | ||
| 003 | DE-627 | ||
| 005 | 20231225144614.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21037/tau-19-774 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1041.xml |
| 035 | |a (DE-627)NLM31252773X | ||
| 035 | |a (NLM)32676405 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhao, Cheng |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A novel cell-free single-molecule unique primer extension resequencing (cf-SUPER) technology for bladder cancer non-invasive detection in urine |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a 2020 Translational Andrology and Urology. All rights reserved. | ||
| 520 | |a BACKGROUND: The clinical diagnostic method for bladder cancer is cystoscopy, an invasive, expensive and inconvenient clinical test. Using urinary cell-free DNA (cfDNA) to develop non-invasive test for bladder cancer was a promising liquid biopsy | ||
| 520 | |a METHODS: To improve the using rate of cfDNA template and decrease the PCR bias for liquid biopsy using urinary cfDNA, we developed a cell-free single-molecule unique primer extension resequencing (cf-SUPER) technology which was done for 29 matched urinary cfDNA and tumor DNA samples of bladder cancer patients to evaluate consistency of mutation profiles. Then, a 22 high mutational frequence genes was selected to form an uriprier panel, which was analyzed in 100 patients (47 bladder cancer cases and 53 controls) using cf-SUPER technology. This performance of the technology was evaluated using bioinformatic tools and clinical samples | ||
| 520 | |a RESULTS: The study showed that cf-SUPER technology can accurately detect mutations with allele fractions even low as 0.01% and the DNA input as low as 1 ng. The consistency of mutation profiles and clinical pathological diagnose between 29 matched urinary cfDNA and tumor DNA samples was respectively 82.76% and 89.66% by using cf-SUPER technology. Using cf-SUPER technology, the sensitivity and specificity were 98%, 94% respectively for uriprier panel in non-invasive test | ||
| 520 | |a CONCLUSIONS: The preliminary work shows that cf-SUPER technology will be a promising method for liquid biopsy. Focusing urinary cfDNA, the non-invasive diagnose and monitoring of bladder cancer can come true by using cf-SUPER technology | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bladder cancer | |
| 650 | 4 | |a next-generation sequencing (NGS) | |
| 650 | 4 | |a non-invasive testing | |
| 650 | 4 | |a single primer extension | |
| 650 | 4 | |a urinary cell-free DNA (urinary cfDNA) | |
| 700 | 1 | |a Pan, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yinhuai |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yuanwei |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Weiqing |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Pei |e verfasserin |4 aut | |
| 700 | 1 | |a Ou, Zhenyu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Mengda |e verfasserin |4 aut | |
| 700 | 1 | |a Xiong, Zhuang |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Ran |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Qiang |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Zhenzhou |e verfasserin |4 aut | |
| 700 | 1 | |a Qi, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Long |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Genming |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Translational andrology and urology |d 2012 |g 9(2020), 3 vom: 03. Juni, Seite 1222-1231 |w (DE-627)NLM219254222 |x 2223-4691 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2020 |g number:3 |g day:03 |g month:06 |g pages:1222-1231 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21037/tau-19-774 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2020 |e 3 |b 03 |c 06 |h 1222-1231 | ||